Program
zimberelimab
Also written as “Zimberelimab”, “GLS-010” and “AB122”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Uterine Cervical Neoplasms · Adenocarcinoma Of Esophagus · Neoplasm Metastasis · Biliary Tract Neoplasms, led by 5 companies.
Drug pageZimberelimab: every studyMany companies study it; this page follows only the 20 they lead. All 51 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Guangzhou Gloria Biosciencesits history only | 74 open or running | phase 3since Aug 19, 2022 | Aug 28, 2018 | Dec 2026phase 2 · NCT05909436 |
| Arcus Biosciencesits history only | 60 open or running | phase 3since Oct 3, 2022 | Jul 17, 2018 | none ahead |
| Gilead Sciencesits history only | 43 open or running | phase 3since Aug 12, 2022 | Apr 26, 2018 | Jun 2028phase 3 · NCT05502237 |
| Otsuka | 22 open or running | phase 3since Jul 3, 2026 | Jul 27, 2021 | Jun 2027phase 1 · NCT04999761 |
| RemeGenits history only | 11 open or running | phase 2since Nov 23, 2023 | Nov 23, 2023 | Jun 30, 2027phase 2 · NCT06155396 |
Also a collaborator on its studies: Merck KGaA, Darmstadt, Germany and Strata Oncology.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Otsuka only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2020Named zimberelimabINNProposed as its International Nonproprietary Name in WHO's List 123 · before, GLS-010, AB122
- Jul 27, 2021First study: phase 1 study in Neoplasm MetastasisFirst studyNCT04999761 · 917 planned · Japan
- Jul 3, 2026Phase 3 study in Biliary Tract NeoplasmsPhase 3 reachedNCT07710885 · 784 planned · Australia, Japan, South Korea and more
Ahead
- Jun 2027Primary completion: phase 1 study in Neoplasm MetastasisNCT04999761
- Apr 30, 2030Primary completion: phase 3 study in Biliary Tract NeoplasmsNCT07710885
TargetBeta
“A human immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 2 Otsuka leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07710885Biliary Tract Neoplasms · Australia, Japan, South Korea and more | 3 | Recruiting | Apr 30, 2030 | 784 |
| NCT04999761Neoplasm Metastasis · Japan | 1 | Recruiting | Jun 2027 | 917 |
How it is read
Names in the registry
- “Zimberelimab”, 10 entries
- “GLS-010”, 6 entries
- “AB122”, 2 entries
- “GLS-012+GLS-010”, 2 entries
- “Zimberelimab (ZIM)”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 7 studies
- Uterine Cervical Neoplasms, 2 studies
- Adenocarcinoma Of Esophagus, 1 study
- Neoplasm Metastasis, 1 study
- Biliary Tract Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.